In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...
Read More
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...
Read MoreIn a nutshell This paper reviewed the adverse (negative) events associated with new treatments in multiple myeloma. Patients should be closely monitored for adverse events. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Treatment includes the use of various types of medications. Adverse events...
Read More
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...
Read MoreIn a nutshell This study analyzed the medical records of DLBCL patients who received consolidative radiotherapy (RT) after chemotherapy to determine if consolidative RT improved survival. This study concluded that consolidative RT might improve survival in DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...
Read More
Video information: After receiving a successful treatment, it’s recommended that patients turn to maintenance therapy to help safeguard their quality of life and help control the residual myeloma cells from developing. The landscape for maintenance therapy continues to expand as the potential effects of new immuno-drugs emerge. Listen in as...
Read More
In a nutshell This article reviewed the use of obinutuzumab for patients with follicular lymphoma who have failed rituximab treatment. The article concluded that obinutuzumab treatment is useful for follicular lymphoma patients who have not responded well to rituximab regimens. Some background Follicular lymphoma (FL) is a common type...
Read More
In a nutshell This study analyzed the results of multiple studies to examine the effect of bortezomib (Velcade) on cardiac risk (heart health) in multiple myeloma. Results showed no effect on cardiac risk with bortezomib-based treatment. The incidence of cardiac events was low across all treatment groups. Some background Many multiple myeloma...
Read More
In a nutshell This study examined the effects of pomalidomide (Pomalyst) in combination with bortezomib (Velcade) and dexamethasone (Decadron) in patients with relapsed or refractory multiple myeloma. This treatment combination was considered safe and effective for previously treated multiple myeloma. Some background Standard treatment for...
Read More
